Illustrative pack image. Actual packaging may differ.
GLIMEFON-PM2 Tablet
High-Strength Triple Combination for Advanced Glycemic Control
Composition
Glimepiride 2 mg + Metformin Hydrochloride 500 mg SR + Pioglitazone 15 mg
- Prescription medicine
- Available to order
Overview
GLIMEFON-PM2 is a potent triple drug combination that integrates Glimepiride (a sulfonylurea), Metformin (a biguanide), and Pioglitazone (a thiazolidinedione). It is specifically formulated for patients with type 2 diabetes mellitus who require intensified therapy for optimal blood glucose regulation.
Key Benefits
- Triple-targeted action: enhances insulin secretion, reduces hepatic glucose production, and improves insulin sensitivity
- Superior HbA1c reduction in patients unresponsive to dual therapy
- Effectively controls both fasting and postprandial glucose levels
- Improves lipid profile and reduces insulin resistance
- Supports long-term glycemic control and β-cell preservation
- Once-daily dosing enhances patient compliance
Indications
- Type 2 Diabetes Mellitus (especially in patients with poor glycemic control on dual therapy)
- Suitable for managing insulin resistance and metabolic syndrome
- Helps in reducing long-term diabetic complications
